What is ADvantage Therapeutics worth?
$81.0Mlast known valuation
ADvantage Therapeutics last raised $13.7M in its Early Stage VC (Jun 2023).
Free account
See the evidence behind this price
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for ADvantage Therapeutics
Create free account
No card required
Funding history
3 rounds| Date | Round | Raised | Post-money | $/share |
|---|---|---|---|---|
| Jun 2023 | Early Stage VC | $13.7M | ▮ | ▮ |
| May 2022 | Seed Round | $275K | ▮ | ▮ |
| Jun 2021 | Early Stage VC | $5.0M | ▮ | ▮ |
How ADvantage Therapeutics's valuation is determined
Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.
For ADvantage Therapeutics, too few pricing signals exist to publish a composite mark; the figures above reflect the most recent observed valuation event. Full methodology →
Frequently asked
- What is ADvantage Therapeutics worth?
- ADvantage Therapeutics's last known valuation is $81.0M.
- How much has ADvantage Therapeutics raised?
- ADvantage Therapeutics has raised $18.7M in total funding across 3 recorded rounds.
- When did ADvantage Therapeutics last raise?
- ADvantage Therapeutics last raised in Jun 2023 (Early Stage VC), raising $13.7M.